Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01576900
Other study ID # Nocturia-SBMP
Secondary ID
Status Completed
Phase N/A
First received February 13, 2012
Last updated November 19, 2014
Start date April 2012
Est. completion date October 2014

Study information

Verified date November 2014
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Observational

Clinical Trial Summary

In patients with nocturia, combinational treatment of DDAVP and SyBeMeP might show better outcomes.

Systemic video instruction might prove to be beneficial by helping patients have better understanding on treatment and replacing healthcare personnel.


Description:

One of main reason of nocturia is known as nocturnal polyuria. For the treatment of nocturia caused by overactive bladder, the combined therapy of anticholinergics plus behavioural modification has been established as the first line therapy. However, nocturia mainly comes from polyuria has been treated with desmopressin pharmacotherapy and the effect of behaviour modification education has not yet evaluated. Therefore, in this study, short term synergistic effect of combinational treatment of desmopressin and SyBeMeP (Systemized Behavioral Modification education Program) comparing desmopressin monotherpy will be evaluated in patients with nocturia.

Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP. Patients will be randomized and assigned to each group at the ratio of 1:1. At screening visit, flowmetry and residual urine measurement, Complete Blood Count (CBC), atypical diabetes mellitus (ADM), electrolytes, urinalysis micro, urine concentration, and demographic examination will be done. Voiding diary will be distributed. At 2nd visit, patients will be randomized and each treatment will be initiated. IPSS, ICIQ-nocturia, and PPTB will be completed. Voiding diary will be distributed. At 3rd visit (2 weeks after from 2nd visit): IPSS, ICIQ-nocturia, and PPTB will be completed. Assess the treatment outcome including voiding diary analysis.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- A patient with nocturia, who visited department of urology as outpatient

- Have not been treated with desmopressin for at least 6 months before

Exclusion Criteria:

- Sleep disorder,

- history of medication for voiding,

- diabetes insipidus,

- diabetes mellitus,

- cardiovascular disease,

- voiding difficulties (including residual urine of more than 100ml),

- small bladder capacity,

- overactive bladder,

- illiteracy,

- psychiatric disorder and having no intention to be enrolled by written agreement

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Behavioral:
SyBeMeP (Systemized Behavioural Modification education Program)
Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site. Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added) During trial, patients will watch SYBeMeP at a specially prepared separate room with computer. After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education.

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (2)

Lead Sponsor Collaborator
Seoul National University Hospital Ferring Pharmaceuticals

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (1)

Cho SY, Lee SL, Kim IS, Koo DH, Kim HJ, Oh SJ. Short-term effects of systematized behavioral modification program for nocturia: a prospective study. Neurourol Urodyn. 2012 Jan;31(1):64-8. doi: 10.1002/nau.21186. Epub 2011 Aug 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Decrease in urinary frequency (No. of nocturia) baseline, 2 week, 1 month, and 3 months No
Secondary Voiding diary indices baseline, 2 weeks, 1 month and 3 months No
Secondary IPSS baseline, 2 weeks, 1 month and 3 months No
Secondary ICIQ-nocturia baseline, 2 weeks, 1 month and 3 months No
Secondary patient's perception of bladder condition (PPTB) baseline, 2 weeks, 1 month and 3 months No
Secondary patient's satisfaction on the education baseline, 2 weeks, 1 month and 3 months No
See also
  Status Clinical Trial Phase
Completed NCT03623880 - Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders N/A
Completed NCT02904759 - Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects Phase 3
Completed NCT02835846 - Investigation of the Effect of the Female Urinary Microbiome on Incontinence Phase 4
Completed NCT02905682 - Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects Phase 3
Completed NCT01684800 - Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women Phase 2
Completed NCT01694498 - Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men Phase 2
Completed NCT01520948 - Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease Phase 3
Completed NCT01222598 - A Study of Minirin Melt in Patients With Nocturia N/A
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Completed NCT01486706 - Efficacy and Safety of Gabapentin in Treating Overactive Bladder Phase 2/Phase 3
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Recruiting NCT05874375 - UCon Treatment of Overactive Bladder (OAB) in Males N/A
Completed NCT01223937 - Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients Phase 3
Withdrawn NCT01018225 - Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness Phase 4
Completed NCT05222477 - Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes N/A
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Completed NCT02440841 - Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon Phase 1
Completed NCT02068560 - The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion N/A
Completed NCT01357356 - Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia Phase 2/Phase 3
Completed NCT02151253 - Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia Phase 2/Phase 3